Roflumilast foam for checkpoint inhibitor skin side effects
Treatments studied
Part of Cancer, Immune system & allergy, Skin clinical trials.
This trial tests a medicated foam (roflumilast) to relieve skin problems like rash, itching, or eczema that can happen during immune checkpoint inhibitor cancer treatment. The goal is to see if the foam helps clear the skin without needing steroid creams or pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are currently on or recently (within 6 months) had treatment with immune checkpoint inhibitors for cancer.
- You have mild, moderate, or severe skin side effects (such as rash, itching, blisters, eczema, or a skin condition called lichenoid or psoriasiform) from this treatment.
- You must be willing to not use steroid creams or pills for your skin side effects for the first 2 weeks of the study.
- You must be willing to avoid certain medicines that interact with the study drug, and if you are on antihistamines, the dose must stay the same during the trial.
- You are not pregnant and agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new foam (roflumilast) applied to the skin to treat seborrheic dermatitis, a condition causing red, flaky patches usually on the scalp or face. It aims to see if the foam reduces redness and scaling better than a placebo.
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
This trial tests whether roflumilast cream can effectively treat psoriasis in skin folds or on the genitals for people who have not had success with other creams. If you have this type of psoriasis and other treatments haven't cleared it up, this study might be an option.
This study tests a foam medication (roflumilast 0.3%) applied to the skin to see if it safely reduces hidradenitis suppurativa (HS) bumps and pain in teens and adults. It might help people with mild-to-moderate HS, especially those who haven't tried this foam before.
Hear when a new Immune-related Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.